Estep J Michael, Younossi Zobair M
a Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.
b Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, Third Floor, 3300 Gallows Road, Falls Church, VA 22042, USA.
Expert Rev Endocrinol Metab. 2010 Mar;5(2):209-215. doi: 10.1586/eem.10.7.
Hepatitis C virus (HCV) and the hepatic manifestation of metabolic syndrome, nonalcoholic fatty liver disease, are the two major causes of chronic liver disease worldwide. Liver histology of both diseases can be associated with steatosis, oxidative stress and fibrogenesis. Although better defined for HCV, approximately 20% of patients with these diseases can also develop cirrhosis or hepatocellular carcinoma. In recent years, it has become clear that the presence of metabolic syndrome and nonalcoholic fatty liver disease negatively impacts HCV-related outcomes, while simultaneously, the progression of HCV may have metabolic consequences in that it encourages or exacerbates insulin resistance. A growing body of evidence suggests that successful treatment of HCV may rely on understanding and addressing the complex and often mutually confounding relationship between HCV and the individual elements that comprise metabolic syndrome.
丙型肝炎病毒（HCV）和代谢综合征的肝脏表现——非酒精性脂肪性肝病，是全球慢性肝病的两大主要病因。这两种疾病的肝脏组织学都可能与脂肪变性、氧化应激和纤维化形成有关。虽然HCV的情况已得到更明确的界定，但这些疾病约20%的患者也可能发展为肝硬化或肝细胞癌。近年来，已明确代谢综合征和非酒精性脂肪性肝病的存在会对HCV相关的转归产生负面影响，而与此同时，HCV的进展可能产生代谢后果，因为它会促进或加剧胰岛素抵抗。越来越多的证据表明，成功治疗HCV可能依赖于理解并解决HCV与构成代谢综合征的各个要素之间复杂且往往相互混淆的关系。
